Multicenter prospective observational study of dupilumab-induced ocular events in atopic dermatitis patients
dc.rights.license | open | en_US |
hal.structure.identifier | Immunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept] | |
dc.contributor.author | COSTEDOAT, Ingrid | |
dc.contributor.author | WALLAERT, M. | |
dc.contributor.author | GAULTIER, A. | |
dc.contributor.author | VASSEUR, R. | |
dc.contributor.author | VANHAECKE, C. | |
dc.contributor.author | VIGUIER, M. | |
dc.contributor.author | CORDELETTE, C. | |
dc.contributor.author | DENOYER, A. | |
dc.contributor.author | FERRIER LE BOUËDEC, M.-C. | |
dc.contributor.author | COUTU, A. | |
dc.contributor.author | LAMIAUX, M. | |
dc.contributor.author | TRAN, T.H.C. | |
dc.contributor.author | LACOUR, J.P. | |
dc.contributor.author | ELMALEH, V. | |
dc.contributor.author | TETART, F. | |
dc.contributor.author | GUEUDRY, J. | |
dc.contributor.author | TAUBER, M. | |
dc.contributor.author | GIORDANO-LABADIE, F. | |
dc.contributor.author | CASSAGNE, M. | |
dc.contributor.author | NOSBAUM, A. | |
dc.contributor.author | OUILHON, C. | |
dc.contributor.author | JACHIET, M. | |
dc.contributor.author | TADAYONI, R. | |
dc.contributor.author | DEZOTEUX, F. | |
dc.contributor.author | STAUMONT-SALLE, D. | |
dc.contributor.author | BOULEAU, J. | |
dc.contributor.author | LABALETTE, P. | |
dc.contributor.author | DOAN, S. | |
dc.contributor.author | SORIA, A. | |
hal.structure.identifier | Immunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept] | |
dc.contributor.author | MORTEMOUSQUE, Bruno | |
hal.structure.identifier | Immunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept] | |
dc.contributor.author | SENESCHAL, Julien | |
dc.contributor.author | BARBAROT, S. | |
dc.contributor.author | FRENCH ATOPIC DERMATITIS NETWORK FROM THE GROUPE DE RECHERCHE SUR L'ECZEMA ATOPIQUE (GREAT), France | |
dc.date.accessioned | 2024-08-30T08:27:38Z | |
dc.date.available | 2024-08-30T08:27:38Z | |
dc.date.issued | 2023 | |
dc.identifier.issn | 0926-9959 | en_US |
dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/201364 | |
dc.description.abstractEn | Background: Although ocular adverse events are frequent in AD patients treated with dupilumab, their characterization remains limited due to a lack of prospective studies with a systematic ophthalmological examination. Objective: To examine the incidence, characteristics and risk factors of dupilumab-induced ocular adverse events. Methods: A prospective, multicenter, and real-life study in adult AD patients treated with dupilumab. Results: At baseline, 27 out of 181 patients (14.9%) had conjunctivitis. At week 16 (W16), 25 out of 27 had improved their conjunctivitis and 2 remained stable and 34 out of 181 patients (18.7%) had dupilumab-induced blepharoconjunctivitis: either de novo (n = 32) or worsening of underlying blepharoconjunctivitis (n = 2). Most events (27/34; 79.4%) were moderate. A multivariate analysis showed that head and neck AD (OR = 7.254; 95%CI [1.938–30.07]; p = 0.004), erythroderma (OR = 5.635; 95%CI [1.635–21.50]; p = 0.007) and the presence of dry eye syndrome at baseline (OR = 3.51; 95%CI [3.158–13.90]; p = 0.031) were independent factors associated with dupilumab-induced blepharoconjunctivitis. Limitations: Our follow-up period was 16 weeks and some late-onset time effects may still occur. Conclusion: This study showed that most dupilumab-induced blepharoconjunctivitis cases are de novo. AD severity and conjunctivitis at baseline were not found to be associated risk factors in this study. © 2023 European Academy of Dermatology and Venereology. | |
dc.language.iso | EN | en_US |
dc.title.en | Multicenter prospective observational study of dupilumab-induced ocular events in atopic dermatitis patients | |
dc.type | Article de revue | en_US |
dc.identifier.doi | 10.1111/jdv.18932 | en_US |
dc.subject.hal | Sciences du Vivant [q-bio]/Immunologie | en_US |
dc.identifier.pubmed | 36732052 | en_US |
bordeaux.journal | Journal of the European Academy of Dermatology and Venereology | en_US |
bordeaux.page | 1056-1063 | en_US |
bordeaux.volume | 37 | en_US |
bordeaux.hal.laboratories | ImmunoConcEpT - UMR 5164 | en_US |
bordeaux.issue | 5 | en_US |
bordeaux.institution | Université de Bordeaux | en_US |
bordeaux.institution | CNRS | en_US |
bordeaux.peerReviewed | oui | en_US |
bordeaux.inpress | non | en_US |
hal.popular | non | en_US |
hal.audience | Internationale | en_US |
hal.export | false | |
dc.rights.cc | Pas de Licence CC | en_US |
bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Journal%20of%20the%20European%20Academy%20of%20Dermatology%20and%20Venereology&rft.date=2023&rft.volume=37&rft.issue=5&rft.spage=1056-1063&rft.epage=1056-1063&rft.eissn=0926-9959&rft.issn=0926-9959&rft.au=COSTEDOAT,%20Ingrid&WALLAERT,%20M.&GAULTIER,%20A.&VASSEUR,%20R.&VANHAECKE,%20C.&rft.genre=article |
Fichier(s) constituant ce document
Fichiers | Taille | Format | Vue |
---|---|---|---|
Il n'y a pas de fichiers associés à ce document. |